By developing and commercializing since 2003 diagnostic products based on fully validated biomarkers that help oncologists to manage leukemia and breast cancer, IPSOGEN is positioned to play an important role in the emerging field of personalized medicine.

The company has developed an integrated approach with R&D capabilities to develop and clinically validate unique biomarkers in-licensed from public institutions.

With more than 80 product references used routinely in 5 continents for the diagnosis, prognosis and monitoring of thousands of patients with leukemia, including its least common forms, IPSOGEN is currently the world leader in blood cancer molecular diagnostics.

The company is now targeting breast cancer and aims to provide currently inaccessible diagnostic information to guide treatment decisions.